### **Overview** Venus Remedies Limited is a research-driven, globally integrated pharmaceutical company headquartered in Panchkula, India. Established in 1989 as Venus Glucose Private Limited, the company has evolved into one of India’s top-tier manufacturers of specialized injectable formulations, with a strong global footprint and a strategic focus on innovation, regulatory excellence, and digital transformation. Venus Remedies ranks among the world’s **top 10 manufacturers of fixed-dose injectable pharmaceuticals** and is positioned within the **global top 500 pharma companies**. The company operates through a dual focus on **generic and specialty formulations**, serving over **90 countries** across emerging and regulated markets. Its consolidated business includes a wholly owned German subsidiary, **Venus Pharma GmbH**, which strengthens its European distribution and regulatory access. --- ### **Core Therapeutic Areas** Venus Remedies targets high-growth, high-unmet-need segments: - **Antimicrobial Resistance (AMR)** – Flagship focus, including novel antibiotics and resistance-breaker therapies. - **Oncology** – Growing portfolio of chemotherapy and supportive care injectables. - **Critical & Super-Specialty Care** – Neurosurgery, pain management, anticoagulants, skin & wound care. - **Natural Products / Herbal Therapeutics** – Via its **RESET** consumer health brand. - **Hemostatics** – Focused on trauma and surgical care innovations. --- ### **Product Portfolio & Growth Drivers** #### Key Products Driving Growth: - **Meropenem & Imipenem-Cilastatin (Carbapenems)** – Venus is India’s **largest exporter of Meropenem**, accounting for ~40% of exports. The product contributes significantly to revenue, with over 120 global marketing authorizations. - **Enoxaparin** – A major anticoagulant with robotic pre-filled syringe (PFS) capabilities; a high-volume, high-growth product with EU-GMP and UNICEF certification. - **Elores** – A patented combination therapy targeting **ESBL/MBL-producing Gram-negative infections**, launched in multiple markets including Saudi Arabia, Oman, and Ecuador. - **VRP-034 (Polymyxin B with Renal Guard Technology)** – A first-in-class, nephrotoxicity-reduced antibiotic; **QIDP-designated by US FDA**, with global patent protection and expected commercial launch in upcoming years. - **Mintide, Sugammadex, Bendamustine, Azacitidine, Fulvestrant** – Recent high-value oncology and supportive care launches with significant future revenue potential. #### Consumer Healthcare: RESET - **RESET** is a science-backed, D2C wellness brand targeting pain, sleep, detox, and mental wellness. - Uses nano-formulations, plant-based ingredients, and AI-driven diagnostics for personalized health recommendations. - Achieved **25x YoY growth** and 20% repeat purchase rate; positioned for expansion in domestic and international markets. --- ### **R&D & Innovation Strategy** Led by the **Venus Medicine Research Centre (VMRC)** – DSIR-approved, GLP-accredited, CPCSEA-compliant – the company drives innovation through: - **Renal Guard Technology** – Proprietary platform to reduce nephrotoxicity of antibiotics like polymyxin B, colistin, and amikacin. - **Antibiotic Resistance Breakers (ARBs)** – Enhance efficacy of existing antibiotics; core to the **PLEA (Preserving Life of Existing Antibiotics)** initiative. - **Novel Drug Delivery Systems (NDDS)** – Including nanotechnology, pulsatile release, targeted delivery. - **Gene Editing (CRISPR-Cas)** – In early development for next-gen antimicrobials; among 3 Indian candidates featured in the **WHO 2023 Global Antibacterial Pipeline Report**. - **Organ-on-a-Chip (OOC)** – India’s **first human Kidney-on-a-Chip lab**, used to validate VRP-034’s safety and accelerate pre-clinical development. #### Key Pipeline in Development: | Candidate | Status | Indication | |--------|--------|------------| | **VRP-034** | Clinical Readiness / Pre-IND | Life-threatening Gram-negative infections (QIDP-designated) | | **VRP-035/VRP-044** | Pre-clinical | Nephroprotective versions of amikacin and colistin | | **VRP-048** | Pre-clinical | Meropenem + MBL inhibitor combo for cUTI and pneumonia | --- ### **Manufacturing & Regulatory Excellence** - **9 Globally Benchmark Facilities**: - **India**: Panchkula (Haryana), Baddi (Himachal Pradesh) - **Germany**: Werne (subsidiary Venus Pharma GmbH) - **EU-GMP, UNICEF, WHO-GDP, PIC/S (Malaysia, Ukraine, Moldova), KSA SFDA, TGA, SAHPRA, and ISO certifications** validate quality and credibility. - **Robotic PFS Line** – For enoxaparin with 20M+ annual capacity; also approved in Malaysia (NPRA), enabling faster global approvals via mutual recognition. - **Central Plant Coordination (PCD)** and **IoT/AI-driven monitoring** ensure efficiency and compliance. --- ### **Global Market Presence & Commercial Strategy** - **International Revenue**: ₹468 crore (72% of total ₹648 crore in FY25), driven by regulated and emerging markets. - **Top Markets**: - **Europe**: Germany, Italy, Spain, UK - **Middle East & Africa**: Saudi Arabia, UAE, Libya, Morocco, Sudan - **Asia**: Thailand, Philippines, Myanmar, Nepal - **Americas**: Mexico, Colombia, Ecuador - **Regulatory Strength**: More than **1,050 marketing authorizations (MAs)** globally, with **430+ active** and plans to **activate 100+ dormant MAs in FY26**. - Strategic **regulatory dossiers in submission** across EU, UK, ASEAN, and LATAM to enter 100 countries by 2025–26. --- ### **Digital Transformation** Venus Remedies is a digital pioneer in the Indian pharma space: - **Davai App**: B2B e-commerce platform for digital order fulfillment; covers 10,000+ stockists in 2,400+ towns. - **SpineNextGen ERP + PharmaWRK + Luna Intelligence**: Integrated digital ecosystem for CRM, forecasting, and field engagement. - **AI & Predictive Analytics**: For **pricing, bid strategies, gross contribution modeling**, and **launch velocity tracking**. - **Customer Delight Online**: Centralized order management system for domestic and international operations. - **WebXR for MedEd**: Immersive product training using 8th Wall platform. - **Fully Paperless Operations** targeted for FY26. --- ### **Strategic Growth Pillars** 1. **Therapeutic Expansion**: - Focus on **oncology, CNS, anti-infectives, and high-gross contribution (GC)** products like Meropenem and Enoxaparin. - Reduced over-reliance on antibiotics; **oncology grew over 30% in EU** in FY24. 2. **Geographic Diversification**: - Strong presence in **PIC/S countries** (32+ including Ukraine, Malaysia); expanding into LATAM, ASEAN, CIS. - Won **UNICEF & PAHO global tenders** – critical for access in underserved markets. 3. **Portfolio Penetration**: - Deepening relationships with **existing partners** (e.g., Cipla, Zydus in CDMO). - Launching **private-label products** in Asia, CIS, and LATAM. 4. **Institutional & Government Business**: - Domestic: Supplying **Pradhan Mantri Bharatiya Jan Aushadhi Kendras**, Indian Railways, state hospitals. - International: Institutional tenders in **Saudi Arabia, Ukraine, Mexico, Peru**. - **100% institutional sales to public hospitals**, targeting 1% market share in key brands. 5. **R&D Commercialization**: - Shifting from **IP creation to value generation**. - In-licensing key assets: **MET-X (MBL inhibitor)** from Infex Therapeutics (UK) for combo development. - Collaborations with **Veeda Clinical Research (India), Nortis Bio (US), Newcells Biotech (UK)**. --- ### **Financial & Operational Highlights (FY25)** - **Total Revenue**: ₹648 crore - **International**: ₹468 crore (72%) - **Product Approvals**: **285 FY25** – record high, primarily for international markets. - **Manufacturing Upgrades**: Automation, debottlenecking, increased batch sizes (e.g., Vancomycin from 36k to 72k units). - **Contract Manufacturing (CDMO)**: Expanded with two new agreements; serving top Indian and international players. - **Patents & IP**: Over **130 granted patents, 125 trademarks, 17 copyrights** globally. - **Government Recognition**: DSIR R&D registration (customs duty exemption), beneficiary of **Pharma PLI scheme (₹10 crore disbursement)**. --- ### **Sustainability & Global Health Impact** - Member of **AMR Industry Alliance, India AMR Innovation Hub, Vivli AMR Registry**. - **Pioneer in AMR R&D**: VMRC contributes 5 of India’s 10 preclinical candidates in the **WHO Antibacterial Pipeline Review**. - **Affordable Access**: Repurposed antibiotics with ARBs to combat resistance in low- and middle-income countries. --- ### **Key Recognition** - **FICCI Healthcare Award 2023** – For Organ-on-a-Chip technology. - **PLI Scheme Beneficiary** – Recognized innovator in the pharmaceutical sector. - **Global Tender Wins** – UNICEF, PAHO, Saudi MoH, INSABI Mexico. ---